Vor Biopharma Inc.
VOR
$2.17
-$0.03-1.36%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -63.63% | 10.51% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 631.58% | 6.32% | |||
| Operating Income | -631.58% | -6.32% | |||
| Income Before Tax | -4,744.15% | -5.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4,744.15% | -5.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4,744.15% | -5.78% | |||
| EBIT | -631.58% | -6.32% | |||
| EBITDA | -643.90% | -6.63% | |||
| EPS Basic | -4,726.01% | 40.65% | |||
| Normalized Basic EPS | -4,631.41% | 40.64% | |||
| EPS Diluted | -4,726.01% | 40.65% | |||
| Normalized Diluted EPS | -4,631.41% | 40.64% | |||
| Average Basic Shares Outstanding | 0.36% | 78.26% | |||
| Average Diluted Shares Outstanding | 0.36% | 78.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||